指南与共识泌尿生殖介入USCTMR

ACR适宜性标准:前列腺癌永久性粒子源近距离放疗

ACR appropriateness criteria: Permanent source brachytherapy for prostate cancer.
指南 / 共识 · Brachytherapy · 2016-12-07

美国放射学会(ACR)多学科专家组基于文献分析与改良Delphi共识法更新了经直肠超声引导经会阴永久性粒子源前列腺近距离放疗的适宜性标准,涵盖患者评估、选择、治疗及植入后剂量检测,并指出该标准仅作参考,最终诊疗责任由治疗临床医生承担。

要点

  • 低危前列腺癌患者行永久性前列腺近距离放疗单药治疗是适宜且有效的根治性治疗,长期肿瘤控制极佳且并发症可接受。
  • 高危患者接受永久性前列腺近距离放疗时应联合补充性外照射放疗(EBRT)及雄激素剥夺治疗。
  • 基于CT的植入后剂量检测应在永久性前列腺近距离放疗后60天内完成,对质量保证至关重要。

核心结论

  • 永久性前列腺近距离放疗是经适当选择的低危至极高危局限性前列腺癌患者的治疗选择之一。
  • 低危患者行单药治疗为适宜且有效的根治性治疗,长期肿瘤控制极佳且并发症可接受。
  • 高危患者接受永久性前列腺近距离放疗时应联合补充性外照射放疗及雄激素剥夺治疗。

研究设计与样本

  • 美国放射学会(ACR)适宜性标准,针对经直肠超声引导经会阴间质永久性粒子源近距离放疗。
  • 每3年由多学科专家组复审,基于同行评议期刊文献的广泛分析及改良Delphi共识法对影像与治疗流程的适宜性进行评分。
  • 证据不足或不确定时,可采用专家意见推荐影像或治疗。

诊断标准与关键数值

  • 低危前列腺癌:永久性前列腺近距离放疗单药治疗为适宜且有效的根治性治疗。
  • 选择性中危患者:可考虑永久性前列腺近距离放疗单药治疗,多参数MRI有助于评估此类患者。
  • 高危患者:接受永久性前列腺近距离放疗时应联合补充性外照射放疗及雄激素剥夺治疗。
  • 盆腔淋巴结受累患者:也可考虑上述联合治疗,但已报道的长期结局有限。
  • 外照射放疗后局部复发:可考虑永久性前列腺近距离放疗,但与毒性风险增加相关。

临床应用与阅片要点

  • 该适宜性标准涵盖患者评估、选择、治疗及植入后剂量检测,仅作参考,最终诊疗责任由治疗临床医生承担。
  • 多参数MRI可用于评估选择性中危患者是否适合永久性前列腺近距离放疗单药治疗。
  • 基于CT的植入后剂量检测应在60天内完成以保证质量。

局限性

  • 该标准仅作参考,最终诊疗责任由治疗临床医生承担。
  • 盆腔淋巴结受累患者接受联合治疗的已报道长期结局有限。
  • 证据不足或不确定时可采用专家意见推荐影像或治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To provide updated American College of Radiology (ACR) appropriateness criteria for transrectal ultrasound-guided transperineal interstitial permanent source brachytherapy.

METHODS AND MATERIALS: The ACR appropriateness criteria are evidence-based guidelines for specific clinical conditions that are reviewed every 3 years by a multidisciplinary expert panel. The guideline development and review include an extensive analysis of current medical literature from peer reviewed journals and the application of a well-established consensus methodology (modified Delphi) to rate the appropriateness of imaging and treatment procedures by the panel. In those instances where evidence is lacking or not definitive, expert opinion may be used to recommend imaging or treatment.

RESULTS: Permanent prostate brachytherapy (PPB) is a treatment option for appropriately selected patients with localized prostate cancer with low to very high risk disease. PPB monotherapy remains an appropriate and effective curative treatment for low-risk prostate cancer patients demonstrating excellent long-term cancer control and acceptable morbidity. PPB monotherapy can be considered for select intermediate-risk patients with multiparametric MRI useful in evaluation of such patients. High-risk patients treated with PPB should receive supplemental external beam radiotherapy (EBRT) along with androgen deprivation. Similarly, patients with involved pelvic lymph nodes may also be considered for such combined treatment but reported long-term outcomes are limited. Computed tomography-based postimplant dosimetry completed within 60 days of PPB is essential for quality assurance. PPB may be considered for treatment of local recurrence after EBRT but is associated with an increased risk of toxicity.

CONCLUSIONS: Updated appropriateness criteria for patient evaluation, selection, treatment, and postimplant dosimetry are given. These criteria are intended to be advisory only with the final responsibility for patient care residing with the treating clinicians.

来源:Brachytherapy,查看原文。版权归原作者所有。

引用

  1. Davis BJ, Taira AV, Nguyen PL, et al. ACR appropriateness criteria: Permanent source brachytherapy for prostate cancer. Brachytherapy. 2016. PMID: 27964905. doi:10.1016/j.brachy.2016.10.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。